396 related articles for article (PubMed ID: 3141002)
21. Axonal transport of proteins and glycoproteins in the rat nigro-striatal pathway and the effects of 6-hydroxydopamine.
Roger LJ; Breese GR; Morell P
Brain Res; 1980 Sep; 197(1):95-112. PubMed ID: 6156743
[TBL] [Abstract][Full Text] [Related]
22. Effect of ischemia on the in vivo release of striatal dopamine, glutamate, and gamma-aminobutyric acid studied by intracerebral microdialysis.
Globus MY; Busto R; Dietrich WD; Martinez E; Valdes I; Ginsberg MD
J Neurochem; 1988 Nov; 51(5):1455-64. PubMed ID: 2902196
[TBL] [Abstract][Full Text] [Related]
23. Tissue levels and in vivo release of tachykinins and GABA in striatum and substantia nigra of rat brain after unilateral striatal dopamine denervation.
Lindefors N; Brodin E; Tossman U; Segovia J; Ungerstedt U
Exp Brain Res; 1989; 74(3):527-34. PubMed ID: 2468514
[TBL] [Abstract][Full Text] [Related]
24. Differential regulation of dopamine release by N-methyl-D-aspartate receptors in rat striatum after partial and extreme lesions of the nigro-striatal pathway.
Andrés ME; Gysling K; Bustos G
Brain Res; 1998 Jun; 797(2):255-66. PubMed ID: 9666143
[TBL] [Abstract][Full Text] [Related]
25. Acute effects of intranigral application of MPP+ on nigral and bilateral striatal release of dopamine simultaneously recorded by microdialysis.
Santiago M; Rollema H; de Vries JB; Westerink BH
Brain Res; 1991 Jan; 538(2):226-30. PubMed ID: 1707325
[TBL] [Abstract][Full Text] [Related]
26. Reserpine pretreatment prevents increases in extracellular striatal dopamine following L-DOPA administration in rats with nigrostriatal denervation.
Kannari K; Tanaka H; Maeda T; Tomiyama M; Suda T; Matsunaga M
J Neurochem; 2000 Jan; 74(1):263-9. PubMed ID: 10617128
[TBL] [Abstract][Full Text] [Related]
27. Evidence that [3H]dopamine is taken up and released from nondopaminergic nerve terminals in the rat substantia nigra in vitro.
Kelly E; Jenner P; Marsden CD
J Neurochem; 1985 Jul; 45(1):137-44. PubMed ID: 3923157
[TBL] [Abstract][Full Text] [Related]
28. Effects of baclofen on striatal 5-HT mediated by the nigrostriatal dopamine system.
Waldmeier PC; Feldtrauer JJ; Kam R; Stöcklin K
Eur J Pharmacol; 1979 Mar; 54(3):279-87. PubMed ID: 428427
[TBL] [Abstract][Full Text] [Related]
29. Long-term survival of intrastriatal dopaminergic grafts: modulation of acetylcholine release by graft-derived dopamine.
Jackisch R; Duschek M; Neufang B; Rensing H; Hertting G; Herman JP
J Neurochem; 1991 Jul; 57(1):267-76. PubMed ID: 2051168
[TBL] [Abstract][Full Text] [Related]
30. Activation of the subthalamic nucleus and pedunculopontine tegmentum: does it affect dopamine levels in the substantia nigra, nucleus accumbens and striatum?
Jaffer A; van der Spuy GD; Russell VA; Mintz M; Taljaard JJ
Neurodegeneration; 1995 Jun; 4(2):139-45. PubMed ID: 7583677
[TBL] [Abstract][Full Text] [Related]
31. Sparing of behavior and basal extracellular dopamine after 6-hydroxydopamine lesions of the nigrostriatal pathway in rats exposed to a prelesion sensitizing regimen of amphetamine.
Moroz IA; Peciña S; Schallert T; Stewart J
Exp Neurol; 2004 Sep; 189(1):78-93. PubMed ID: 15296838
[TBL] [Abstract][Full Text] [Related]
32. Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats.
Smith AD; Kozlowski DA; Bohn MC; Zigmond MJ
Exp Neurol; 2005 Jun; 193(2):420-6. PubMed ID: 15869944
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of brain-derived neurotrophic factor and neurotrophin-3 on neurochemical and behavioral deficits associated with partial nigrostriatal dopamine lesions.
Altar CA; Boylan CB; Fritsche M; Jones BE; Jackson C; Wiegand SJ; Lindsay RM; Hyman C
J Neurochem; 1994 Sep; 63(3):1021-32. PubMed ID: 7519657
[TBL] [Abstract][Full Text] [Related]
34. Regulation of neurotensin-containing neurons in the rat striatum and substantia nigra. Effects of unilateral nigral lesion with 6-hydroxydopamine on neurotensin content and its binding site density.
Masuo Y; Pélaprat D; Montagne MN; Scherman D; Rostène W
Brain Res; 1990 Mar; 510(2):203-10. PubMed ID: 1970504
[TBL] [Abstract][Full Text] [Related]
35. Cyclosporin A attenuates the decrease in tyrosine hydroxylase immunoreactivity in nigrostriatal dopaminergic neurons and in striatal dopamine content in rats with intrastriatal injection of 6-hydroxydopamine.
Matsuura K; Makino H; Ogawa N
Exp Neurol; 1997 Aug; 146(2):526-35. PubMed ID: 9270064
[TBL] [Abstract][Full Text] [Related]
36. In vivo measurement of spontaneous release and metabolism of dopamine from intrastriatal nigral grafts using intracerebral dialysis.
Zetterström T; Brundin P; Gage FH; Sharp T; Isacson O; Dunnett SB; Ungerstedt U; Björklund A
Brain Res; 1986 Jan; 362(2):344-9. PubMed ID: 2417666
[TBL] [Abstract][Full Text] [Related]
37. Sensorimotor impairment and elevated levels of dopamine metabolites in the neostriatum occur rapidly after intranigral injection of 6-hydroxydopamine or gamma-hydroxybutyrate in awake rats.
Altar CA; O'Neil S; Marshall JF
Neuropharmacology; 1984 Mar; 23(3):309-18. PubMed ID: 6427648
[TBL] [Abstract][Full Text] [Related]
38. Interactions of dopaminergic and GABAergic neurotransmission: impact of 6-hydroxydopamine lesions into the substantia nigra of rats.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1995 Oct; 275(1):237-44. PubMed ID: 7562556
[TBL] [Abstract][Full Text] [Related]
39. The effects of dopamine-depleting brain lesions on the electrophysiological activity of rat substantia nigra dopamine neurons.
Hollerman JR; Grace AA
Brain Res; 1990 Nov; 533(2):203-12. PubMed ID: 2126975
[TBL] [Abstract][Full Text] [Related]
40. Intrastriatal dopaminergic grafts restore inhibitory control over striatal cholinergic neurons.
Herman JP; Lupp A; Abrous N; Le Moal M; Hertting G; Jackisch R
Exp Brain Res; 1988; 73(2):236-48. PubMed ID: 3145893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
